Bicocca Open Archive

Logo unimib boa
INVERNIZZI, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.430
AS - Asia 13.831
EU - Europa 11.875
SA - Sud America 2.354
AF - Africa 243
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 16
Totale 51.765
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.975
SG - Singapore 5.285
IT - Italia 2.904
CN - Cina 2.866
HK - Hong Kong 2.533
RU - Federazione Russa 2.199
BR - Brasile 1.899
VN - Vietnam 1.719
DE - Germania 1.612
SE - Svezia 1.489
IE - Irlanda 1.262
GB - Regno Unito 670
AT - Austria 341
UA - Ucraina 322
CA - Canada 291
FR - Francia 240
ID - Indonesia 234
IN - India 234
AR - Argentina 211
FI - Finlandia 204
KR - Corea 197
NL - Olanda 159
TR - Turchia 154
BD - Bangladesh 117
MX - Messico 103
JP - Giappone 98
PL - Polonia 92
ZA - Sudafrica 91
IQ - Iraq 85
DK - Danimarca 84
ES - Italia 72
EC - Ecuador 67
BE - Belgio 42
CO - Colombia 40
MY - Malesia 37
MA - Marocco 32
PY - Paraguay 32
LT - Lituania 29
PK - Pakistan 28
SA - Arabia Saudita 28
UZ - Uzbekistan 27
VE - Venezuela 27
PE - Perù 25
CL - Cile 24
DZ - Algeria 24
CZ - Repubblica Ceca 23
EG - Egitto 22
IL - Israele 21
IR - Iran 21
PT - Portogallo 21
AE - Emirati Arabi Uniti 20
KE - Kenya 19
CH - Svizzera 18
PH - Filippine 18
TW - Taiwan 18
GR - Grecia 17
RO - Romania 16
UY - Uruguay 15
JO - Giordania 14
AZ - Azerbaigian 13
JM - Giamaica 13
AU - Australia 12
CR - Costa Rica 11
SK - Slovacchia (Repubblica Slovacca) 11
BO - Bolivia 10
ET - Etiopia 9
RS - Serbia 9
AL - Albania 8
PA - Panama 8
A2 - ???statistics.table.value.countryCode.A2??? 7
KZ - Kazakistan 7
MM - Myanmar 7
NO - Norvegia 7
SC - Seychelles 7
SN - Senegal 7
EU - Europa 6
HN - Honduras 6
NP - Nepal 6
TN - Tunisia 6
DO - Repubblica Dominicana 5
HU - Ungheria 5
OM - Oman 5
TT - Trinidad e Tobago 5
GA - Gabon 4
GH - Ghana 4
GT - Guatemala 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
NZ - Nuova Zelanda 4
QA - Qatar 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BH - Bahrain 3
MK - Macedonia 3
MU - Mauritius 3
NG - Nigeria 3
SR - Suriname 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
Totale 51.715
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.833
Singapore 3.077
Hong Kong 2.512
Ashburn 1.950
Fairfield 1.778
Woodbridge 1.345
Dublin 1.209
Chandler 1.144
Wilmington 1.035
Frankfurt am Main 1.018
Houston 999
Milan 866
Seattle 772
New York 699
Cambridge 621
Santa Clara 522
Dallas 514
Ho Chi Minh City 514
Dearborn 501
Princeton 469
Hefei 449
Chicago 447
Los Angeles 414
Beijing 411
Jacksonville 375
Hanoi 364
Vienna 269
London 233
Lawrence 229
Moscow 214
Nanjing 214
Altamura 213
The Dalles 209
Shanghai 198
Jakarta 191
Seoul 185
Buffalo 180
São Paulo 174
Rome 143
San Diego 138
Boardman 117
Munich 114
Nuremberg 107
Guangzhou 87
Council Bluffs 85
Dong Ket 78
Helsinki 75
Rio de Janeiro 74
Tokyo 73
Toronto 72
Andover 67
Lachine 62
Warsaw 62
Florence 61
Salt Lake City 60
Hangzhou 56
San Jose 55
Haiphong 54
Nanchang 54
Monza 51
Brooklyn 50
Changsha 50
Columbus 50
Da Nang 49
Johannesburg 49
Stockholm 47
Orem 46
Ottawa 45
Biên Hòa 43
Montreal 43
Boston 42
Shenyang 42
Tampa 42
Turin 42
Bari 41
Bologna 41
Hebei 41
Brussels 40
Jinan 39
Belo Horizonte 38
Pune 38
Elk Grove Village 37
Falls Church 37
Norwalk 37
Phoenix 37
Poplar 34
Brasília 33
Denver 33
Fremont 33
Lissone 33
Turku 33
Atlanta 32
Tianjin 32
Washington 32
Chennai 31
Jiaxing 31
Lappeenranta 31
Ha Long 30
Ninh Bình 30
Zhengzhou 29
Totale 33.635
Salva come PNG Salva come JPEG
Nome #
Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms 691
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 518
Validation of the Italian version of fisk fatigue severity score (FFSS) and PBC-40 454
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 436
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model 413
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 385
Exploring the landscape of steatotic liver disease in the general US population 372
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 343
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 324
Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes 310
A short version of a HRQol questionnaire for Italian and Japanese patients with PBC 309
A second update on mapping the human genetic architecture of COVID-19 308
Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA 294
Mapping the human genetic architecture of COVID-19 292
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 288
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 279
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 279
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload 276
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 272
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 271
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 271
Precision medicine in primary biliary cholangitis 270
Understanding short bowel syndrome: Current status and future perspectives 269
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 268
Risk stratification in primary sclerosing cholangitis 267
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 266
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 262
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 260
It's as if PBC didn’t exist: The illness experience of women affected by primary biliary cirrhosis 256
DCLK1, a putative novel stem cell marker in human cholangiocarcinoma 256
Endocrinology and Metabolic Diseases (Including Diabetes) 255
Dermatological Complications After Solid Organ Transplantation 255
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 254
Better end points needed in primary sclerosing cholangitis trials 252
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development 252
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 251
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 248
High rates of 30-day mortality in patients with cirrhosis and COVID-19 245
Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy 244
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 244
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 243
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 241
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 239
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective 238
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 238
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 238
The X-factor in primary biliary cirrhosis: Monosomy X and xenobiotics 235
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation 234
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 231
Autoimmune liver diseases 230
New Therapeutic Targets in Autoimmune Cholangiopathies 229
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 228
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 228
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth 227
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 226
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 226
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 225
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 225
Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study 225
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 224
Y chromosome loss in male patients with primary biliary cirrhosis 221
Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells 220
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 220
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the " Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 218
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 218
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 218
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 217
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 216
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 215
Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2−/− mice and human primary sclerosing cholangitis 215
Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis 213
AISF position paper on liver disease and pregnancy 213
The challenges of primary biliary cholangitis: What is new and what needs to be done 213
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma 212
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion 212
The Seat of Life. What a Lesson from the Stigmatized Saints 209
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 209
Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis 208
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth 207
“I Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism 207
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 206
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 205
Prognostic models in primary biliary cholangitis 202
Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice 201
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 198
MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response 198
Artificial Intelligence and liver: Opportunities and barriers 197
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 196
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 194
Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism 194
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 193
Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b 192
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 191
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth 191
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 191
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 191
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 190
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 190
Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation 189
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 187
Totale 25.066
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.413
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.413
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.864 0 0 0 0 0 640 725 751 472 458 389 429
2021/20223.372 349 274 450 243 204 240 132 212 147 214 312 595
2022/20235.371 601 1.340 437 474 462 807 153 297 443 94 150 113
2023/20244.867 131 159 172 426 549 1.098 753 188 362 248 86 695
2024/202511.516 792 1.268 738 608 973 478 672 489 1.171 1.576 1.039 1.712
2025/202613.624 3.048 1.671 2.080 2.746 2.909 1.170 0 0 0 0 0 0
Totale 53.486